“Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature” (2022) Biomolecules and Biomedicine, 22(2), pp. 300–301. doi:10.17305/bjbms.2021.6419.